Clinical Trials Logo

Inflammatory Myopathy clinical trials

View clinical trials related to Inflammatory Myopathy.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04687111 Active, not recruiting - Hypertension Clinical Trials

Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation

PARABLE
Start date: December 16, 2015
Phase: Phase 2
Study type: Interventional

Sacubitril-valsartan, an Angiotensin Receptor Blocker-Neprilysin Inhibitor (ARNI), currently marketed for the management of heart failure, has been shown to reduce cardiovascular morbidity and mortality in stage C heart failure with reduced ejection fraction. In stage C HFpEF, sacubitril-valsartan has also been shown to reduce left atrial volume index measured using echocardiography over a 9 month timeframe. The PARABLE study investigates the hypothesis that sacubitril-valsartan can provide benefits in terms of left atrial structure and function as well as left ventricular structure and function in asymptomatic (stage A/B HFpEF) patients. This is a prospective, randomised, double-blind, double-dummy, phase II study design. The patient population will have hypertension and/or diabetes together with preserved ejection fraction, elevated natriuretic peptide (NP) and abnormal left atrial volume index (LAVI, > 28 mL/m2).